Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

65.71
+1.251.94%
Volume:1.62M
Turnover:106.77M
Market Cap:6.19B
PE:-137.92
High:66.38
Open:64.78
Low:64.50
Close:64.46
52wk High:66.38
52wk Low:17.05
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.30
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:252.59
PE(LYR):-229.47

Loading ...

Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

Simply Wall St.
·
Aug 20

Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares

Reuters
·
Aug 20

Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates

Reuters
·
Aug 14

Travere Therapeutics Grants 38,940 Inducement RSUs to 12 New Employees

Reuters
·
Aug 13

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

TIPRANKS
·
Aug 12

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

Reuters
·
Aug 07

Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
Aug 06

Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61

THOMSON REUTERS
·
Aug 06

Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships

TIPRANKS
·
Aug 06

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

Reuters
·
Aug 06

Does FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?

Simply Wall St.
·
Aug 06

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Travere Therapeutics, Inc. : Jefferies Raises Target Price to $64 from $54

THOMSON REUTERS
·
Aug 05

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Benzinga Earnings
·
Aug 05

Travere Therapeutics, Inc. : TD Cowen Raises Target Price to $75 from $60

THOMSON REUTERS
·
Aug 05

Travere Therapeutics, Inc. : Guggenheim Raises Target Price to $75 from $65

THOMSON REUTERS
·
Aug 05